HIV-Positive Liver Transplant Does not Alter the Latent Viral Reservoir in Recipients With Antiretroviral Therapy-Suppressed HIV
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
The latent viral reservoir (LVR) remains a major barrier to HIV-1 curative strategies. It is unknown whether receiving a liver transplant from a donor with HIV might lead to an increase in the LVR because the liver is a large lymphoid organ. We found no differences in intact provirus, defective provirus, or the ratio of intact to defective provirus between recipients with ART-suppressed HIV who received a liver from a donor with (n = 19) or without HIV (n = 10). All measures remained stable from baseline by 1 year posttransplant. These data demonstrate that the LVR is stable after liver transplantation in people with HIV. Clinical Trials Registration. NCT02602262 and NCT03734393.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:228 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 228(2023), 9 vom: 02. Nov., Seite 1274-1279 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Benner, Sarah E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Retroviral Agents |
|---|
| Anmerkungen: |
Date Completed 16.11.2023 Date Revised 12.03.2024 published: Print ClinicalTrials.gov: NCT03734393, NCT02602262 Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiad241 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358808782 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358808782 | ||
| 003 | DE-627 | ||
| 005 | 20240312233109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiad241 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM358808782 | ||
| 035 | |a (NLM)37379584 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Benner, Sarah E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HIV-Positive Liver Transplant Does not Alter the Latent Viral Reservoir in Recipients With Antiretroviral Therapy-Suppressed HIV |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.11.2023 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT03734393, NCT02602262 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a The latent viral reservoir (LVR) remains a major barrier to HIV-1 curative strategies. It is unknown whether receiving a liver transplant from a donor with HIV might lead to an increase in the LVR because the liver is a large lymphoid organ. We found no differences in intact provirus, defective provirus, or the ratio of intact to defective provirus between recipients with ART-suppressed HIV who received a liver from a donor with (n = 19) or without HIV (n = 10). All measures remained stable from baseline by 1 year posttransplant. These data demonstrate that the LVR is stable after liver transplantation in people with HIV. Clinical Trials Registration. NCT02602262 and NCT03734393 | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a HIV cure | |
| 650 | 4 | |a latent viral reservoir | |
| 650 | 4 | |a liver | |
| 650 | 4 | |a organ transplant | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 700 | 1 | |a Zhu, Xianming |e verfasserin |4 aut | |
| 700 | 1 | |a Hussain, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Florman, Sander |e verfasserin |4 aut | |
| 700 | 1 | |a Eby, Yolanda |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez, Reinaldo E |e verfasserin |4 aut | |
| 700 | 1 | |a Ostrander, Darin |e verfasserin |4 aut | |
| 700 | 1 | |a Rana, Meenakshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ottmann, Shane |e verfasserin |4 aut | |
| 700 | 1 | |a Hand, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Price, Jennifer C |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, Marcus R |e verfasserin |4 aut | |
| 700 | 1 | |a Wojciechowski, David |e verfasserin |4 aut | |
| 700 | 1 | |a Simkins, Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Stosor, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Sapna A |e verfasserin |4 aut | |
| 700 | 1 | |a Aslam, Saima |e verfasserin |4 aut | |
| 700 | 1 | |a Malinis, Maricar |e verfasserin |4 aut | |
| 700 | 1 | |a Haidar, Ghady |e verfasserin |4 aut | |
| 700 | 1 | |a Massie, Allan |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Melissa L |e verfasserin |4 aut | |
| 700 | 1 | |a Odim, Jonah |e verfasserin |4 aut | |
| 700 | 1 | |a Morsheimer, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Quinn, Thomas C |e verfasserin |4 aut | |
| 700 | 1 | |a Laird, Gregory M |e verfasserin |4 aut | |
| 700 | 1 | |a Siliciano, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Balagopal, Ashwin |e verfasserin |4 aut | |
| 700 | 1 | |a Segev, Dorry L |e verfasserin |4 aut | |
| 700 | 1 | |a Durand, Christine M |e verfasserin |4 aut | |
| 700 | 1 | |a Redd, Andrew D |e verfasserin |4 aut | |
| 700 | 1 | |a Tobian, Aaron A R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 228(2023), 9 vom: 02. Nov., Seite 1274-1279 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:228 |g year:2023 |g number:9 |g day:02 |g month:11 |g pages:1274-1279 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiad241 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 228 |j 2023 |e 9 |b 02 |c 11 |h 1274-1279 | ||